마카

Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials.

1. Clinics (Sao Paulo). 2025 Feb 21;80:100602. doi: 10.1016/j.clinsp.2025.100602. eCollection 2025. Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials. de Aquino ACQ(1), Sarmento ACA(2), Teixeira RL

Botanical extracts as anti-aging preparations for the skin: a systematic review.

2. Drugs Aging. 2010 Dec 1;27(12):973-85. doi: 10.2165/11584420-000000000-00000. Botanical extracts as anti-aging preparations for the skin: a systematic review. Hunt KJ(1), Hung SK, Ernst E. Author information: (1)Complementary Medicine, Peninsula College of Medicine and Dentistry, University o

Maca (L. meyenii) for improving sexual function: a systematic review.

3. BMC Complement Altern Med. 2010 Aug 6;10:44. doi: 10.1186/1472-6882-10-44. Maca (L. meyenii) for improving sexual function: a systematic review. Shin BC(1), Lee MS, Yang EJ, Lim HS, Ernst E. Author information: (1)Division of Clinical Medicine, School of Oriental Medicine, Pusan National Univ

The Role of Dietary Ingredients in Mental Energy - A Scoping Review of Randomized Controlled Trials.

1. J Am Nutr Assoc. 2024 Feb;43(2):167-182. doi: 10.1080/27697061.2023.2244031. Epub 2023 Aug 10. The Role of Dietary Ingredients in Mental Energy - A Scoping Review of Randomized Controlled Trials. Nieman KM(1), Zhu Y(2), Tucker M(2), Koecher K(2). Author information: (1)Katalyses, Ankeny, Iowa, USA. (2)Bell Institute of Health and Nutrition, General Mills, Inc, Minneapolis, Minnesota, USA. Low mental energy can contribute to decreased productivity, altered life balance, decreased physical performance, and ultimately affect quality of life. As such, there is a great demand for food and beverage products that positively impact mental energy. Numerous products claim to alter mental energy making continued review of the scientific evidence critical. The objective of this study was to conduct a scoping review of randomized controlled trials to evaluate the effect of 18 dietary ingredients on mental energy outcomes in adults without severe disease. Methods: A literature search, completed using PubMed, resulted in the identification of 2261 articles, 190 of which met eligibility from initial abstract review. Full-text review was completed on the 190 studies which resulted in 101 articles that fully met eligibility for inclusion in this study. The search strategy for two ingredients did not yield any eligible studies, leaving studies for 16 ingredients that were extracted and summarized by reported significantly improved outcomes for cognition, mood and perceived feelings, and sleep assessments. The preliminary results for several dietary ingredients directionally suggested a mental energy benefit (≥20% of outcomes), including ashwagandha, chamomile, dark chocolate, ginseng, green tea, lavender, lion's mane mushroom, maca, tart cherries, turmeric, and valerian root. The results of this scoping review suggest that of the 16 dietary ingredients reviewed, 11 may be promising for further exploration on their potential benefits in supporting mental energy. Given consumer demand and market growth for food and beverage products that positively impact mental energy; continued efforts in assessment method alignment and additional evaluation in well-designed trials is warranted.KEY TEACHING POINTSOf the 16 dietary ingredients reviewed, 11 (ashwagandha, chamomile, dark chocolate, ginseng, green tea, lavender, lion's mane mushroom, maca, melatonin foods, turmeric, and valerian root) may be promising for further exploration on their potential mental energy benefits.Dark chocolate, ginseng, ashwagandha, and lion's mane mushroom were the most promising ingredients for further evaluation in the cognition domain of the ingredients evaluated.Turmeric, maca, lavendar, and ashwagandha were the most promising ingredients for further evaluation in the mood and perceived feelings domain of the ingredients evaluated.Ashwagandha, chamomile, green tea, melatonin foods, valerian root were the most promising ingredients for further evaluation in the sleep domain of the ingredients evaluated.Additional, well-designed, consistent, clinical trials and systematic reviews are warranted as the challenge of heterogeneity in mental energy study design remains. DOI: 10.1080/27697061.2023.2244031 PMID: 37561965 [Indexed for MEDLINE]

Maca reduces blood pressure and depression, in a pilot study in postmenopausal women.

2. Climacteric. 2015 Feb;18(1):69-78. doi: 10.3109/13697137.2014.929649. Epub 2014 Aug 7. Maca reduces blood pressure and depression, in a pilot study in postmenopausal women. Stojanovska L(1), Law C, Lai B, Chung T, Nelson K, Day S, Apostolopoulos V, Haines C. Author information: (1)* Centre for Chronic Disease Prevention and Management, College of Health and Biomedicine, Victoria University , Victoria , Australia. OBJECTIVE: Lepidium meyenii (Maca) has been used for centuries for its fertility-enhancing and aphrodisiac properties. In an Australian study, Maca improved anxiety and depressive scores. The effects of Maca on hormones, lipids, glucose, serum cytokines, blood pressure, menopausal symptoms and general well-being in Chinese postmenopausal women were evaluated. METHODS: A randomized, double-blind, placebo-controlled, cross-over study was conducted in 29 postmenopausal Hong Kong Chinese women. They received 3.3 g/day of Maca or placebo for 6 weeks each, in either order, over 12 weeks. At baseline, week 6 and week 12, estradiol, follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), thyroid stimulating hormone (TSH), full lipid profiles, glucose and serum cytokines were measured. The Greene Climacteric, SF-36 Version 2, Women's Health Questionnaire and Utian Quality of Life Scales were used to assess the severity of menopausal symptoms and health-related quality of life. RESULTS: There were no differences in estradiol, FSH, TSH, SHBG, glucose, lipid profiles and serum cytokines amongst those who received Maca as compared to the placebo group; however, significant decreases in diastolic blood pressure and depression were apparent after Maca treatment. CONCLUSIONS: Maca did not exert hormonal or immune biological action in the small cohort of patients studied; however, it appeared to reduce symptoms of depression and improve diastolic blood pressure in Chinese postmenopausal women. Although results are comparable to previous similar published studies in postmenopausal women, there might be a cultural difference among the Chinese postmenopausal women in terms of symptom reporting. DOI: 10.3109/13697137.2014.929649 PMID: 24931003 [Indexed for MEDLINE]

Subjective effects of Lepidium meyenii (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomised, double-blind clinical trial.

3. Andrologia. 2009 Apr;41(2):95-9. doi: 10.1111/j.1439-0272.2008.00892.x. Subjective effects of Lepidium meyenii (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomised, double-blind clinical trial. Zenico T(1), Cicero AF, Valmorri L, Mercuriali M, Bercovich E. Author information: (1)Department of Urology, Morgagni-Pierantoni Hospital, Forlì, Italy. t.zenico@ausl.fo.it Lepidium meyenii (Maca) is a cultivated root belonging to the brassica family used in the Andean region for its supposed aphrodisiac properties. We carried out a double-blind clinical trial on 50 Caucasian men affected by mild erectile dysfunction (ED), randomised to treatment with Maca dry extract, 2400 mg, or placebo. The treatment effect on ED and subjective well-being was tested administrating before and after 12 weeks the International Index of Erectile Function (IIEF-5) and the Satisfaction Profile (SAT-P). After 12 weeks of treatment, both Maca- and placebo-treated patients experienced a significant increase in IIEF-5 score (P < 0.05 for both). However, patients taking Maca experienced a more significant increase than those taking placebo (1.6 +/- 1.1 versus 0.5 +/- 0.6, P < 0.001). Both Maca- and placebo-treated subjects experienced a significant improvement in psychological performance-related SAT-P score, but the Maca group higher than that of placebo group (+9 +/- 6 versus +6 +/- 5, P < 0.05). However, only Maca-treated patients experienced a significant improvement in physical and social performance-related SAT-P score compared with the baseline (+7 +/- 6 and +7 +/- 6, both P < 0.05). In conclusion, our data support a small but significant effect of Maca supplementation on subjective perception of general and sexual well-being in adult patients with mild ED. DOI: 10.1111/j.1439-0272.2008.00892.x PMID: 19260845 [Indexed for MEDLINE]

A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction.

4. CNS Neurosci Ther. 2008 Fall;14(3):182-91. doi: 10.1111/j.1755-5949.2008.00052.x. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. Dording CM(1), Fisher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. Author information: (1)Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA. cdording@partners.org We sought to determine whether maca, a Peruvian plant, is effective for selective-serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction. We conducted a double-blind, randomized, parallel group dose-finding pilot study comparing a low-dose (1.5 g/day) to a high-dose (3.0 g/day) maca regimen in 20 remitted depressed outpatients (mean age 36+/-13 years; 17 women) with SSRI-induced sexual dysfunction. The Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ) were used to measure sexual dysfunction. Ten subjects completed the study, and 16 subjects (9 on 3.0 g/day; 7 on 1.5 g/day) were eligible for intent-to-treat (ITT) analyses on the basis of having had at least one postbaseline visit. ITT subjects on 3.0 g/day maca had a significant improvement in ASEX (from 22.8+/-3.8 to 16.9+/-6.2; z=-2.20, P=0.028) and in MGH-SFQ scores (from 24.1+/-1.9 to 17.0+/-5.7; z=-2.39, P=0.017), but subjects on 1.5 g/day maca did not. Libido improved significantly (P<0.05) for the ITT and completer groups based on ASEX item #1, but not by dosing groups. Maca was well tolerated. Maca root may alleviate SSRI-induced sexual dysfunction, and there may be a dose-related effect. Maca may also have a beneficial effect on libido. DOI: 10.1111/j.1755-5949.2008.00052.x PMCID: PMC6494062 PMID: 18801111 [Indexed for MEDLINE] Conflict of interest statement: CHRISTINA DORDING, MD: Research Support: Abbott Laboratories, Alkermes, Aspect Medical Systems, Astra‐Zeneca, Bristol‐Myers Squibb Company, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, J& J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, Novartis, Organon Inc., PamLab, LLC, Pfizer Inc, Pharmavite, Roche, Sanofi/Synthelabo, Solvay Pharmaceuticals, Inc., Wyeth‐Ayerst Laboratories Speakers' Honoraria: Wyeth MAURIZIO FAVA, MD: Advisory/Consulting: Aspect Medical Systems, Astra‐Zeneca, Bayer AG, Biovail Pharmaceuticals, Inc., BrainCells, Inc. Bristol‐Myers Squibb Company, Cephalon, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eli Lilly & Company, EPIX Pharmaceuticals, Fabre‐Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals Inc., GlaxoSmithkline, Grunenthal GmBH, Janssen Pharmaceutica, Jazz Pharmaceuticals, J & J Pharmaceuticals, Knoll Pharmaceutical Company, Lundbeck, MedAvante, Inc., Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab, LLC, Pfizer Inc, PharmaStar, Pharmavite, Roche, Sanofi/Synthelabo, Sepracor, Solvay Pharmaceuticals, Inc., Somaxon, Somerset Pharmaceuticals, Wyeth‐Ayerst Laboratories Speaking: Astra‐Zeneca, Boehringer‐Ingelheim, Bristol‐Myers Squibb Company, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, Novartis, Organon Inc., Pfizer Inc, PharmaStar, Wyeth‐Ayerst Laboratories Equity Holdings: Compellis, MedAvante Royalty/patent, other income: none DAVID MISCHOULON, MD, PHD: Research Support: Lichtwer Pharma GmbH, Bristol‐Myers Squibb Company, Cederroth, Laxdale (Amarin), Nordic Naturals, SwissMedica Advisory/Consulting: None Speaking: Bristol‐Meyers Squibb Company, Pamlab LLC, Nordic Naturals, Virbac, Pfizer, Wyeth, AstraZeneca, Cephalon, Janssen, Lilly Equity Holdings: None Royalty/patent, other income: PMS Escape (patent co‐holder) ANDREW A. NIERENBERG, MD: Grant/Research Support: Bristol‐Myers Squibb, Cederroth, Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Eli Lilly, NARSAD, NIMH, Pfizer, Stanley Foundation, Wyeth‐Ayerst Advisory/Consulting: Bristol‐Myers Squibb, Genaissance, GlaxoSmithKline, Innapharma, Janssen Pharmaceutica, Eli Lilly, Novartis, Pfizer, Sepracor, Shire, Somerset Equity Holdings: None Speaking/Honoraria: Bristol‐Myers Squibb, Cyberonics, Forest Pharmaceuticals, GlaxoSmithKline, Eli Lilly, Wyeth‐Ayerst GEORGE I. PAPAKOSTAS, MD: Research Support: Bristol‐Myers Squibb Company, Pamlab LLC, Pfizer Inc. Advisory/Consulting: Aphios Corporation, Evotec Ltd., GlaxoSmithKline, Inflabloc Pharmaceuticals, Inc, Jazz Pharmaceuticals, Pamlab, LLC Honoraria: Evotec Ltd., GlaxoSmithKline, Inflabloc Pharmaceuticals, INC., Jazz Pharmaeuticals, Pamlab, LLC, Pfizer, Inc., Titan Pharmaceuticals Equity Holdings: none Royalty/patent, other income: none SHAMSAH SONAWALLA, M.D. Research Support: Abbott Laboratories, Alkermes, Aspect Medical Systems, Astra‐Zeneca, Bristol‐Myers Squibb Company, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, J& J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, Novartis, Organon Inc., PamLab,LLC, Pfizer Inc, Pharmavite, Roche, Sanofi/Synthelabo, Solvay Pharmaceuticals, Inc., Wyeth‐Ayerst Laboratories All other authors report no conflicts of interest.

Effect of Lepidium meyenii (Maca), a root with aphrodisiac and fertility-enhancing properties, on serum reproductive hormone levels in adult healthy men.

5. J Endocrinol. 2003 Jan;176(1):163-8. doi: 10.1677/joe.0.1760163. Effect of Lepidium meyenii (Maca), a root with aphrodisiac and fertility-enhancing properties, on serum reproductive hormone levels in adult healthy men. Gonzales GF(1), Córdova A, Vega K, Chung A, Villena A, Góñez C. Author information: (1)Instituto de Investigaciones de la Altura, and Department of Biological and Physiological Sciences (Faculty of Sciences and Philosophy), Universidad Peruana Cayetano Heredia, PO 1843, Lima, Peru. Lepidium meyenii (Maca) is a Peruvian hypocotyl that grows exclusively between 4000 and 4500 m in the central Andes. Maca is traditionally employed in the Andean region for its supposed aphrodisiac and/or fertility-enhancing properties. This study was a 12-week double-blind, placebo-controlled, randomized, parallel trial in which active treatment with different doses of Maca Gelatinizada was compared with a placebo. The study aimed to test the hypothesis that Maca has no effect on serum reproductive hormone levels in apparently healthy men when administered in doses used for aphrodisiac and/or fertility-enhancing properties. Men aged between 21 and 56 Years received 1500 mg or 3000 mg Maca. Serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin, 17-alpha hydroxyprogesterone, testosterone and 17-beta estradiol were measured before and at 2, 4, 8 and 12 weeks of treatment with placebo or Maca (1.5 g or 3.0 g per day). Data showed that compared with placebo Maca had no effect on any of the hormones studied nor did the hormones show any changes over time. Multiple regression analysis showed that serum testosterone levels were not affected by treatment with Maca at any of the times studied (P, not significant). In conclusion, treatment with Maca does not affect serum reproductive hormone levels. DOI: 10.1677/joe.0.1760163 PMID: 12525260 [Indexed for MEDLINE]